Welcome to our dedicated page for Shl Telemedicine SEC filings (Ticker: SHMLF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SHL Telemedicine Ltd. (SHMLF) files with the U.S. Securities and Exchange Commission as a foreign private issuer under the Securities Exchange Act of 1934. The company indicates that it uses Form 20-F for its annual reports and Form 6-K to furnish current information, such as press releases and shareholder communications.
The Form 6-K filings highlighted in the available data focus on capital structure and shareholder actions. They include press releases titled “SHL Telemedicine launches rights offering,” “SHL Telemedicine successfully completes rights offering and capital increase,” and “SHL’s shareholders confirm increase of share capital.” Another 6-K furnishes a press release titled “SHL announces Invitation to a Special General Meeting,” reflecting governance and meeting-related disclosures.
On this SEC filings page for SHMLF, users can access these 6-K reports as they are made available from the SEC’s EDGAR system. Each filing typically contains an explanatory note and an exhibit table, with the press release attached as Exhibit 99.1. Reviewing these documents can help investors understand how SHL Telemedicine Ltd. raises capital through rights offerings, how share capital increases are approved, and how special general meetings are convened.
Alongside direct access to the filings, AI-powered tools on this page can summarize the key points in lengthy documents, highlight the main terms of rights offerings or capital increases, and clarify the nature of shareholder approvals described in the exhibits. This can make it easier to interpret SHL Telemedicine Ltd.’s Form 6-K and Form 20-F disclosures without reading every page in detail.
SHL Telemedicine Ltd CEO Arnon David has filed an initial ownership report showing existing equity awards, not new trades. The Form 3 lists several stock option grants over Ordinary Shares with exercise prices of CHF 2.75 and CHF 3.25, all expiring on September 5, 2030. These options are scheduled to become exercisable on different dates between September 5, 2025 and September 5, 2028, providing long-term, equity-based incentives tied to the company’s future share performance.
SHL Telemedicine Ltd director Carni Orna has filed an initial statement of beneficial ownership on Form 3. The filing, as summarized here, does not list any reportable transactions or derivative positions, indicating this is a baseline disclosure of insider status rather than an active trade.
SHL Telemedicine Ltd director Ido Nouberger filed a Form 3 reporting his ownership of the company’s ordinary shares. The filing shows he holds 1,504,224 ordinary shares directly. It also reports 3,832,720 ordinary shares owned indirectly through Value Base Ltd. and certain affiliates.
The footnote explains that Mr. Nouberger, together with Victor Shamrich, controls Value Base Ltd. and that he disclaims beneficial ownership of the indirectly held shares except to the extent of his pecuniary interest. The entries are reported as holdings rather than new buy or sell transactions.
SHL Telemedicine Ltd director Nir Shlomo Rotenberg has reported his initial share ownership. The filing shows direct ownership of 175,562 Ordinary Shares. It also reports indirect beneficial ownership of 3,165,620 Ordinary Shares held by Danbar Finance Ltd., a private investment group in Israel where he serves as Chairman, director and partner. Rotenberg disclaims beneficial ownership of the Danbar-held shares except to the extent of his pecuniary interest in them.
SHL Telemedicine director Yehoshua Abramovich reported his initial ownership in the company. He directly holds 46,109 Ordinary Shares and a series of stock options with an exercise price of CHF 17.02 per share, expiring on December 9, 2027, covering a total of 18,000 underlying Ordinary Shares vesting in multiple 1,500-share tranches.
SHL Telemedicine Ltd director Offer Itamar reported existing option holdings, not new trades. The filing lists multiple options over Ordinary Shares, each covering 12,500 underlying shares with exercise prices of CHF 2.75 or CHF 3.25, exercisable between September 16, 2026 and September 16, 2029 and expiring on September 16, 2031.
SHL Telemedicine Ltd CFO Lior Haalman has filed an initial Form 3 reporting direct holdings of stock options linked to the company’s ordinary shares. The filing lists several option positions, each referencing 40,000 underlying ordinary shares, with exercise prices of CHF 3.2500 or CHF 2.7500.
These options become exercisable on different dates between February 13, 2026 and February 13, 2029, and each position carries an expiration date of February 13, 2031. A footnote clarifies that all exercise prices are denominated in Swiss francs (CHF).
SHL Telemedicine major shareholders Danbar Finance Ltd, Miri Wulkan and Nir Rotenberg report updated stakes in the company’s American Depositary Shares. Danbar beneficially owns 3,165,620 ordinary shares, or 8.5% of the class. Wulkan beneficially owns 3,656,148 shares, or 9.9%, combining 490,528 shares held directly with Danbar’s holdings. Rotenberg beneficially owns 3,341,182 shares, or 9.0%, including 175,562 shares held directly plus Danbar’s stake.
These percentages are based on 37,059,946 ordinary shares outstanding as of December 3, 2025. On December 2, 2025, Danbar bought 2,374,215 shares at an average price of CHF 0.60, while Wulkan bought 367,896 shares and Rotenberg bought 81,000 shares at the same price. On December 4, 2025, Rotenberg purchased an additional 67,562 shares at CHF 0.78. The amendment also notes that former reporting person Matan Wulkan is no longer a shareholder or director of Danbar and no longer has or shares any voting or dispositive power over any of the issuer’s ordinary shares, including those held by Miri Wulkan.
SHL Telemedicine Ltd. received additional capital from Value Base-related investors through a completed rights offering, and their ownership position has been updated. The reporting group, including Value Base Ltd., Value Base Hedge Fund Ltd. (as general partner of a limited partnership), and individuals Ido Nouberger and Victor Shamrich, now reports beneficial ownership of 5,624,944 ordinary shares, representing approximately 15.18% of SHL’s outstanding ordinary shares, based on 37,059,946 shares outstanding as of December 3, 2025.
In the rights offering, the group subscribed in full at approximately $0.76 per ordinary share, investing about $3.2 million in total. Within this, Mr. Nouberger purchased 1,128,168 shares for about $0.8 million, Mr. Shamrich acquired 216,000 shares for about $0.2 million, Value Base acquired 1,708,077 shares for about $1.3 million, and the limited partnership acquired 1,166,463 shares for about $0.9 million. The amendment also details how these direct holdings translate into indirect and aggregate beneficial ownership percentages for each reporting person.
SHL Telemedicine Ltd. filed a Form 6-K to inform investors that it has successfully completed a rights offering and related capital increase. The company reports that this was announced in a press release dated December 3, 2025, titled “SHL Telemedicine successfully completes rights offering and capital increase,” which is attached to the report as an exhibit. The filing is signed by the Chief Financial Officer, Lior Haalman, on behalf of the company.